Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Hybrigenics    ALHYG   FR0004153930

HYBRIGENICS (ALHYG)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on HYBRIGENICS
04/25 HYBRIGENICS : full year 2015 results
04/05 HYBRIGENICS : rsquo; inecalcitol strengthens key patent protection in the United..
01/07 HYBRIGENICS : Recent Findings from Hybrigenics Has Provided New Information abou..
01/06 HYBRIGENICS : receives green light for a double-blind placebo-controlled Phase I..
2014 HYBRIGENICS : 2014 first-half results and highlights
2014 HYBRIGENICS : successfully raised € 4.6 million
2014 HYBRIGENICS : invests in its genomic capabilities
2014 HYBRIGENICS' : patent estate of inhibitors of ubiquitin-specific proteases is ex..
2014 HYBRIGENICS : revenus et trésorerie au premier semestre 2014
2013 HYBRIGENICS : Hybrigenics' General Meeting highlights - Focus on inecalcitol rec..
2013 HYBRIGENICS : Update on the clinical study of inecalcitol in chronic lymphocytic..
2013 HYBRIGENICS : Hybrigenics' technology platform applied to the study of the aging..
2013 HYBRIGENICS : Hybrigenics' Technology Platform Successfully Applied to the Study..
2013 HYBRIGENICS : 2012 revenues and update on the clinical study of inecalcitol in c..
2013 HYBRIGENICS : launches a new service to screen interactions between small molecu..
2012 HYBRIGENICS : green ligt for two European patents protecting new oral formulatio..
2012 HYBRIGENICS : launches a new website
2012 HYBRIGENICS : Hybrigenics' first half 2012 revenues of EUR 2 million at the same..
2012 HYBRIGENICS : Hybrigenics' General Meeting Highlights
2012 HYBRIGENICS : Bryan, Garnier & Co initiates coverage of Hybrigenics with a targe..
2012 HYBRIGENICS : Bryan Garnier initiates coverage of Hybrigenics with a target pric..
2012 HYBRIGENICS : completed its private placement to institutional investors up to E..
2012 HYBRIGENICS : gets approval and financing for a phase II clinical trial of oral ..
Advertisement
Financials (€)
Sales 2016 5,30 M
EBIT 2016 -4,69 M
Net income 2016 -4,63 M
Finance 2016 3,99 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 5,19x
EV / Sales 2017 5,57x
Capitalization 31,5 M
More Financials
Chart HYBRIGENICS
Duration : Period :
Hybrigenics Technical Analysis Chart | ALHYG | FR0004153930 | 4-Traders
Full-screen chart
Technical analysis trends HYBRIGENICS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 1,50 €
Spread / Average Target 70%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Rémi Delansorne CEO, Director & Head-Investor Relations
Alain Munoz Chairman
Guillaume Floch Chief Financial Officer
Jean-François Dufour-Lamartinie Head-Clinical Research & Development
Piet Serrure Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
HYBRIGENICS-21.30%33
INCYTE CORPORATION-5.14%19 381
QUINTILES IMS HOLDINGS..12.93%19 089
CELLTRION, INC.--.--%9 846
SEATTLE GENETICS, INC.49.13%9 474
LONZA GROUP AG9.44%9 150
More Results